Global Multiple Sclerosis Treatment Market is Growing with 4.5% CAGR in the Forecast Period of 2020 to 2027

Global Multiple Sclerosis Treatment Market is expected to grow with the CAGR of 4.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-multiple-sclerosis-treatment-market

Global multiple sclerosis treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global multiple sclerosis treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In April 2018, Merck KGaA has received approval for Mavenclad (Cladribine) by United Arab Emirates Ministry of Health and Prevention for MS symptoms treatment in adults’ patients. This approval allowed the company to accelerate it growth in several regions of multiple sclerosis treatment market.

Novartis AG, is the dominating player in the global multiple sclerosis treatment market. The other key players existing in the market are Genzyme Corporation (A Subsidiary of Sanofi), Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceuticals Industries Ltd.), F. Hoffmann-La Roche Ltd, Merck KGaA, Mallinckrodt, Pfizer Inc., Hikma Pharmaceuticals PLC, Par Pharmaceutical (a subsidiary of Endo International plc), Mylan N.V., Acorda Therapeutics, Inc., Biogen, CELGENE CORPORATION (A Subsidiary of Bristol-Myers Squibb Company), Lannett, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Bayer AG, Amneal Pharmaceuticals LLC, Adamas Pharmaceuticals, Inc. among others.

Multiple Sclerosis Treatment MarketNovartis AG

Novartis AG is headquartered in Basel, Switzerland. The company focuses on innovating new solutions for various health care challenges in fields of cancer, cardiovascular, immunology and neuroscience among more. The company has two business segments including Innovative Medicines, Sandoz, in these Innovative Medicines is the market focused segment. The company has wide product categories such as cancer, cardiovascular, renal & metabolism, immunology & dermatology, ophthalmology, neuroscience, respiratory in which neuroscience is the market focused category.

For instance,

  • In July 2019, Novartis AG received the Chinese National Medical Products Administration (NMPA) approval for Gilenya used for treatment of relapsing forms of multiple sclerosis (RMS) in adults and children of age 10 years and above. This approval received by the company enhanced its sales and revenue in the market.

The company has a wide presence across Americas, Asia-Pacific, Europe/Middle East /Africa. The company also has various subsidiary companies such as Novartis Argentina S.A., Buenos Aires (Argentina), Novartis Australia Pty Ltd (Australia), Novartis Austria GmbH, Vienna (Austria), Novartis Pharma NV, Vilvoorde (Belgium) and Sandoz (China) Pharmaceutical (China) among others.

Genzyme Corporation (A Subsidiary of Sanofi)

Genzyme Corporation (A Subsidiary of Sanofi) is headquartered in Massachusetts, U.S. founded in the 1980’s. The company is focused to make a positive impact on the lives of patients. The company has wide product portfolio including Aldurazyme, Alprolix, Aubagio, Cablivi, Cerdelga, Cerezyme, Clolar, Dupixent, Elitek, Eloctate, Eloxantin, Fabrazyme, Jevtana, Kevzara, Lemtrada, Libtayo, Lumizyme, Sarclisa, Axotere, Zaltrap in which Aubagio, Lemtrada are the market focused products.

  • In April 2020, Genzyme Corporation obtained positive data from the phase 2b clinical trial of BTK inhibitor (SAR442168) when administered in multiple sclerosis patients. This product has been shown to reduce the neuroinflammation and neurodegeneration symptoms associated with multiple sclerosis. The result obtained helped the company to proceed through other product approval process.

The company has presence across Asia, Middle East & Africa, and the Americas. The company has various subsidiaries such as Genzyme Ireland Ltd (Ireland), Genzyme Portugal S.A. (Portugal), Genzyme Canada Inc. (Canada), Imtix SangStat (Switzerland) GmbH (Switzerland) and Genzyme Austria G.m.b.H. (Austria) among others.

Merck KGaA

Merck KGaA is headquartered in Darmstadt, Germany. The company is engaged in providing solutions in the field of healthcare, life science and performance materials with a passion for technology and love for science. The company operates its business through multiple segments which are life science, healthcare, performance materials in which life science is the market focused segment. The company has various product categories such as anadelumab, Veyvondi- vonicog alfa, vipdomet- algoliptin and metformin, vipidia- a healthcare, life science, performance materials in which healthcare is the market focused category.

  • In April 2019, Merck KGaA presented the data regarding the safety and efficacy of MAVENCLAD for treatment of remitting –relapsing multiple sclerosis. This initiative helped the company to get recognized for its innovative drug portfolio used for multiple sclerosis treatment.

The company is present in Africa, Asia, Europe, Latin America, North America, and Oceania. The company has various subsidiaries which are Sigma-Aldrich (OM) Ltd. (Greece), Merck Foundation gGmbH(Germany), Merck S.A.(Venezuela), iOnctura SA (Switzerland), Merck Ltd.(U.K) and Fluka Chemical Corp.(U.S.), among others.